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Abstract
Purpose Second-line endocrine therapy (ET) for estrogen receptor (ER)-positive and human epidermal growth factor 2 
(HER2)-negative metastatic breast cancer (MBC) is offered based on the response to first-line ET. However, no clinical 
trials have evaluated the efficacy and safety of secondary ETs in patients with poor responses to initial ET. This study evalu-
ated the efficacy of second-line ET in ER-positive and HER2-negative postmenopausal MBC patients with low or very low 
sensitivity to initial ET.
Methods This multicenter prospective observational cohort study evaluated the response of 49 patients to second-line ETs 
in postmenopausal MBC patients with low or very low sensitivity to initial ET. The primary endpoint was the clinical benefit 
rate (CBR) for 24 weeks.
Results Of the 49 patients assessed, 40 (82%) received fulvestrant in the second line, 5 (10%) received selective estrogen 
receptor modulators, 3 (6%) received aromatase inhibitors (AIs) alone, and 1 received everolimus with a steroidal AI. The 
overall CBR was 44.9% [90% confidence interval (CI): 34.6–57.6, p = 0.009]; CBR demonstrated similar significance across 
the progesterone receptor-positive (n = 39, 51.3%, 90% CI: 39.6–65.2, p = 0.002), very low sensitivity (n = 17, 58.8%, 90% 
CI: 42.0–78.8, p = 0.003), and non-visceral metastases (n = 25, 48.0%, 90% CI: 34.1–65.9, p = 0.018) groups. The median 
progression-free survival was 7.1 months (95% CI: 5.6–10.6).
Conclusion Second-line ET might be a viable treatment option for postmenopausal patients with MBC with low and very 
low sensitivity to initial ET. Future studies based on larger and independent cohorts are needed to validate these findings.
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Introduction
Breast cancer with inoperable distant metastasis or 
recurrence has a poor prognosis. Therefore, therapies 
for metastatic breast cancers (MBCs) intend to prolong 
survival and improve the quality of life [1, 2]. Systemic 
therapies play a major role in the treatment of MBC, but 
local therapies including surgery and radiotherapy play 
less important roles. Overall, therapeutic strategies are 
selected based on the age, disease-free interval, extent of 
disease, and the biology of breast cancers, including hor-
mone receptor (HR) and human epidermal growth factor 2 
(HER2) status and extent of the disease. Among the novel 
chemotherapeutic agents and targeted therapies, first-line 
endocrine therapy (ET) continues to be the gold stand-
ard for treating HR-positive and HER2-negative MBC as 
it provides a good quality of life with a lower incidence 
of adverse events. Unfortunately, certain patients fail to 
respond to first-line ET owing to resistance [3]. Second-
line therapies after initial ET are offered based on the 
response to first-line ET [4], as the durations of response 
to second and subsequent-lines of therapy are substantially 
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lower than those of the prior therapy [5, 6]. Patients with 
good responses to first-line ET should be offered ET in the 
second line [4]. Conversely, those not responding to first-
line ET are usually offered chemotherapy instead, owing 
to the likelihood of primary or acquired resistance [3]. 
However, there is no clear clinical definition of resistance 
to ET.
A new classification developed by the second Interna-
tional Consensus Guidelines for Advanced Breast Can-
cer (ABC2) clarifies ET sensitivity based on the clinical 
response to initial ET. These guidelines propose the fol-
lowing classification of ET sensitivity in HR-positive ABC 
based on the time from ET induction to progression [7]: 
patients with recurrence during the first two years after the 
induction of adjuvant ET or with progression during the first 
three months after the induction of first-line ET are consid-
ered to have “very low” ET sensitivity, whereas those with 
recurrence at two to five years after the initiation of adjuvant 
ET or progression within three to nine months after the initi-
ation of first-line ET are considered to have “low” sensitivity 
[3]. The others are stratified into medium or high sensitiv-
ity groups. In patients with “very low” or “low” endocrine 
sensitivity based on the ABC2 criteria, the clinical advan-
tages of second-line ET remain unclear. To our knowledge, 
no clinical trials have evaluated the efficacy and safety of 
the numerous available secondary ETs in patients with poor 
response to initial ET. Previously, we reported the reasons 
for selection of secondary ETs in this unique subgroup [8]. 
Majority of patients and physicians selected secondary ET 
based on its therapeutic effect, while 28% based on the side 
effects.
The mechanisms of action of recently developed ETs for 
breast cancer differ from those of the existing drugs. Ful-
vestrant lacks partial agonistic effects on ER, unlike tamox-
ifen; instead, it downregulates ER expression in breast can-
cer cells, and is therefore classified as a selective estrogen 
receptor downregulator (SERD) [3, 9, 10]. Everolimus is a 
mammalian target of rapamycin (mTOR) inhibitor; mTOR is 
situated downstream in the PI3K/AKT pathway and is a key 
signaling molecule that mediates cancer cell proliferation. 
In breast cancer that has acquired resistance to non-steroidal 
aromatase inhibitors, progression-free survival (PFS) can be 
extended by the combined administration of mTOR inhibi-
tors with other endocrine therapies [11–13]. However, the 
preferred endocrine agents in the second-line setting have 
not been well identified. Accordingly, this study aimed to 
evaluate the efficacy and safety of second-line ETs and var-
ious agents used to treat ER-positive and HER2-negative 
postmenopausal MBC with unfavorable clinical responses to 
primary ET (i.e. “low” or “very low” sensitivity to primary 
ET); it also intended to determine the clinical characteristics 




This multicenter prospective observational study, namely, 
HORSE-BC, included patients receiving second-line ETs 
between February 2016 and January 2017 [8, 14]. The 
study protocol was approved by our institutional review 
boards, and all patients provided written informed consent. 
The inclusion criteria were as follows: (1) postmenopausal 
patients with histologically diagnosed breast cancer, (2) a 
diagnosis of either (a) stage IV breast cancer and inoper-
able distant metastasis at the first visit or (b) breast cancer 
with progression or recurrence caused by distant metas-
tasis after treatment with curative intent, with or without 
measurable lesions, (3) patients planning to receive ET 
for MBC, (4) those with Eastern Cooperative Oncology 
Group performance status (PS) scores of zero to one, (5) 
those who received previous ET using any agent, either 
as (a) continuous postoperative adjuvant therapy with 
recurrence within five years after starting ET or (b) initial 
treatment for MBC with disease progression within nine 
months after starting ET, (6) either received no previous 
chemotherapy for breast cancer or pre- or postoperative 
chemotherapy within the past six months, (7) received no 
previous radiotherapy for breast cancer within the past 
14 days. Cases in which ≥ 1% of the tumor cells stained 
positive for ER were considered ER-positive, and HER2-
negative cases were defined as having immunohistochem-
istry scores of 0/1 + or gene copy numbers < 2.0. “Very 
low” sensitivity to initial ET was defined as recurrence 
within the first two years during adjuvant ET or progres-
sion within three months of initial ET for ABC. “Low” 
sensitivity to initial ET was defined as the recurrence after 
first two to five years during adjuvant ET or progression 
within three to nine months of initial ET for ABC.
The treatment choices included various agents that are 
approved by the Japanese regulatory authority for use as 
ET for postmenopausal breast cancer. The various treat-
ment strategies were thoroughly explained by the attending 
physician and the final decision was made by the patients. 
The safety of the patients and efficacy of the strategy were 
closely monitored. The treatment groups included a SERM 
group [those who received tamoxifen or toremifene, which 
are selective estrogen receptor modulators (SERMs)], an 
AI group (those who received anastrozole, letrozole, or 
exemestane), a SERD group [those who received fulves-
trant, which is a selective estrogen receptor downregulator 
(SERD)], and an mTORi group (those who received any 
ET with everolimus, which is an mTOR inhibitor).
The primary endpoint was the clinical benefit rate 
(CBR), defined as achievement of a complete response 
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(CR), partial response (PR), or stable disease (SD) for 
24 weeks. The secondary endpoints included the follow-
ing: (1) response rate (RR): the proportion of patients 
whose best overall response in the target population with 
measurable lesions was CR or PR in 6 months, (2) PFS: 
the period from the registration day to either the day on 
which progression was determined or the day of death 
from any cause, whichever was earlier, (3) overall sur-
vival (OS): the period from the day of registration to 
death from any cause, (4) time to treatment failure (TTF): 
the period from the day of registration to either the day 
when progression was determined, death occurred from 
any cause, or the day of discontinuation of the protocol 
treatment, whichever was earlier, (5) time to chemother-
apy (TTC): the period from the day of registration to the 
day of first administration of chemotherapy, (6) adverse 
events observed from registration to the discontinuation 
of protocol treatment, evaluated in all treated cases using 
the common terminology criteria for adverse events ver-
sion 4.0. The therapeutic effect was evaluated by imaging 
methods such as computed tomography after 3 or 6 months 
from the initiation of second-line treatment. The response 
evaluation criteria in solid tumors version 1.1 was used 
for assessment. All clinical data and disease character-
istics were collected with the use of a case-report form. 
This trial has been registered in the UMIN Clinical Trials 
Registry, UMIN000019556.
Statistical analyses
Secondary ET for breast cancer with low-sensitivity to 
ET provides a CBR of at least 30% using newer endocrine 
agents; the expected CBR was 50%. The null hypothesis of 
a CBR of 30% was tested with a one-sided α of 5%. Further, 
90% confidence intervals (CIs) were calculated for hypoth-
esis tests. Assuming the use of an accurate binomial test, 
the required number of cases with α = 0.05 (one-tailed) and 
β = 0.2 was estimated to be 43. Univariate analyses of pre-
dictive factors with respect to the CBR for 6 months were 
performed for hypothesis tests with a one-sided α of 5% and 
90% CIs. Similarly, predictive factors for response rate for 
six months was calculated. These analyses for predictive fac-




A total of 56 patients were enrolled, of whom 7 were 
excluded based on the inclusion criteria. Overall, data 
from 49 patients were analyzed further. The patient 
characteristics are shown in Table 1. The median age was 
65.8 (range 41–88) years and the median body mass index 
was 23.9 (16.4–31.9) kg/m2. All patients were ER-positive 
and 80% (39/49) were progesterone receptor (PgR)-nega-
tive. Most patients had a baseline PS of zero or one, 89.8% 
(44/49) and 10.2% (5/49) had invasive ductal and lobular 
carcinoma, respectively. Further, 6.1% (3/49) were TNM 
stage I, 38.8% (19/49) were stage II, 36.7% (18/49) were 
stage III, and 18.4% (9/49) were stage IV based on stag-
ing at the initial diagnosis. Of the patients 49.0% (24/49) 
had visceral metastases, whereas the others had non-vis-
ceral metastases including those of the bone and lymph 
nodes; 36.7% (18/49) had single metastatic sites, and the 
remaining had multiple sites. Postoperative recurrence was 
detected in 81.6% (40/49); the median duration of adjuvant 
ET was 30.5 (5.3–58.9) months. Of patients with post-
operative recurrence, 50% (20/40) received adjuvant/neo 
adjuvant chemotherapy. De novo stage IV breast cancer 
was observed in 18.4% (9/49); the median duration of first-
line ET was 5 (2.3–10.8) months. Overall, 88.1% (37/42), 
4.8% (2/42), and 7.1%(3/42) received non-steroidal AIs, 
steroidal AIs, and SERM as adjuvant ET, respectively. In 
de novo stage IV cases, 88.9% (8/9) were treated with AIs 
or SERM [11.1% (1/9)] in the first-line. Overall, of the 
total cases, 40 (81.6%, 40/49), 5 (10.2%), 5 (6.1%), and 
1 (2.0%) received fulvestrant, SERMs, an mTOR inhibi-
tor with a steroidal AI, and AI alone, respectively, in the 
second-line setting. Of the patients who had a very low 
response, 76.5% (13/17) experienced recurrence within 
the first two years during adjuvant ET and 23.5% (4/17) 
experienced progression within three months of the initial 
ET for metastatic breast cancer. Of patients who had a 
low response, 84.3% (27/32) experienced recurrences at 
two to five years after the initiation of adjuvant ET and 
15.6% (5/32) experienced progression within three to nine 
months after the initiation of first-line ET.
CBR and RR
The overall CBR was 44.9% (90% CI: 34.6–57.6, p = 0.009), 
with similar significance across the following subgroups: 
PgR-positive: n = 10, 51.3%, 90% CI: 39.6–65.2, p = 0.002; 
very low sensitivity: n = 17, 58.8%, 90% CI: 42.0–78.8, 
p = 0.003; non-visceral metastases: n = 25, 48.0%, 90% CI: 
34.1–65.9, p = 0.018) (Table 2). The CBR in PgR-nega-
tive patients was not statistically significant. As shown in 
Table 3, the overall RR was 8.2% (90% CI: 4.1–17.7%). 
The RR was relatively favorable in the very low sensitiv-
ity (n = 17, 11.8%, 90% CI: 5.0–32.6%) and PgR-negative 
(10.0%, 90% CI 3.7–39.4%) subgroups. The fulvestrant 





The median follow-up time was 10.8 months. The median 
PFS of the entire cohort (n = 49) was 7.1 (95% CI: 5.6–10.6) 
months, and the 1-year PFS rate was 34.1% (95% CI: 
21.2–47.4%; Fig. 1a). The one-year OS, TTF, and TTC rates 
were 93.8% (95% CI: 82.0–98.0%; Fig. 2a), 32.0% (95% 
CI: 19.5–45.2%; Fig. 3a), and 73.2% (95% CI: 57.4–83.9%; 
Supplementary figure 1a), respectively. In the fulvestrant-
only subgroup (n = 40), the median PFS was 6.7 (95% CI: 
5.6–9.6) months and the 1-year PFS rate was 30.0% (95% 
CI: 16.8–44.4%; Fig. 1b). The 1-year OS, TTF, and TTC 
rates were 94.9% (95 CI: 81.2–98.7%; Fig. 2b), 27.5% (95% 
CI: 14.9–41.7%; Fig. 3b), and 69.9% (95% CI: 52.0–82.2%; 
Supplementary figure 1b), respectively.
Adverse events
The adverse events (≥ grade 3) are presented in Table 4. A 
total of twelve AEs were observed in this cohort. In the ful-
vestrant group (total patients N = 40), abnormal blood lev-
els of aspartate transaminase, total bilirubin, gamma-gluta-
myltransferase, and fatigue were reported. In the AI group 
(N = 3), two and one patients had depression and insomnia, 
respectively, whereas in the everolimus with exemestane 
group (N = 1), one, one, two, and one patients had interstitial 
pneumonia, appetite loss, fatigue (one patient had it twice), 
and oral mucositis, respectively.
Discussion
To our knowledge, this is the first study to assess the efficacy 
of sequential second-line ETs in postmenopausal ER-posi-
tive and HER2-negative MBC with lower endocrine sensi-
tivity. We first evaluated the clinical significance of the effi-
cacy of second-line ETs in ER-positive and HER2-negative 
postmenopausal MBC in cases where primary ET did not 
demonstrate favorable clinical benefits with relative safety. 
Over 20 years have elapsed since the Hortobagyi algorism 
was established [4], and additional next-generation ETs 




Patients in our analytic cohort (N = 49)
Mean Mini–max
Age (years) 65.8 41–88
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Sensitivity to primary ET














BMI body mass index; ER estrogen receptor; PgR progesterone recep-
tor; PS performance status; IDC invasive ductal carcinoma; ILC 
invasive lobular carcinoma; ET endocrine therapy; SERM selective 




 mTORi + AI 1 2.0
Table 1  (continued)
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have been available for routine clinical use for HR-positive 
and HER2-negative MBC. Fulvestrant, a selective estrogen 
receptor degrader, was selected for the majority of patients 
in our cohort; a lack of cross-reactivity with tamoxifen or 
AIs was observed. Therefore, cancers that progress during 
ET might remain sensitive to fulvestrant [15, 16]. Ellis et al. 
reported that in the first-line setting, fulvestrant (500 mg) 
improves outcomes of HR-positive advanced breast can-
cer compared to those with AIs [17]. The clinical efficacy 
of first-line fulvestrant (500 mg) is also supported by the 
results of the phase III double-blind FALCON trial, which 
assessed patients with locally advanced or metastatic breast 
cancers using a strict definition for ET-naïve disease [13]. 
There might be some distinct resistant mechanisms between 
aromatase inhibitor and fulvestrant. Although aromatase 
inhibition is prone to resistance generated by ESR1 muta-
tions [18], fulvestrant does seem to retain activity against 
tumors that harbor an ESR1 mutation [19]. Further study 
is needed to clarify these mechanisms. Our results provide 
additional data on the clinical efficacy of second-line ET, 
and fulvestrant in particular, for patients with poor response 
to first-line ETs. Unfortunately, the considerably small 
sample sizes of the individual ET subgroups (i.e. SERMs, 
mTOR inhibitors, and AIs) in our cohort might not provide 
adequate statistical power; future trials on various agents, 
Table 2  Predictive factors for 




% 90% CI p value
All 49 44.9 34.6 – 57.6 0.009
Fulvestrant 40 40.0 29.2 – 54.2 0.063
PgR-positive 10 51.3 39.6 – 65.3 0.002
PgR-negative 39 20.0 8.7 – 50.7 0.617
Very low sensitivity 17 58.8 42.0 – 78.8 0.003
Low sensitivity 32 39.4 27.8 – 55.2 0.088
Visceral 24 41.7 28.2 – 60.3 0.074
Non-visceral 25 48.0 34.1 – 65.9 0.018





All 49 8.2 4.1 – 17.7
Fulvestrant 40 2.5 0.9 – 11.3
PgR positive 10 7.7 3.6 – 18.7
PgR negative 39 10.0 3.7 – 39.4
Very low sensitivity 17 11.8 5.0 – 32.6
Low sensitivity 32 6.1 2.5 – 17.9
Visceral 24 8.3 3.5 – 24.0
Non-visceral 25 8.0 3.4 – 23.1
Fig. 1  Kaplan–Meier curves for progression free survival. a All patients (N = 49), b fulvestrant (n = 40). CI confidence interval
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including cyclin-dependent kinase (CDK) inhibitors in addi-
tion to SERMs, mTOR inhibitors, and AIs, are warranted in 
the second-line setting after the endocrine responses of low 
sensitivity to first-line ET.
We subsequently evaluated the predictive factors (non-
visceral metastases, PgR-positivity, and very low sensitivity; 
P value < 0.05) for the efficacy of second-line ETs as second-
ary endpoints. Sub-analyses from prospective randomized 
trials in the first-line setting have already demonstrated the 
clinical efficacy of fulvestrant in patients with non-visceral 
metastases; however, no significant clinical differences were 
observed between fulvestrant and AIs alone in cases with 
visceral metastases [13]. It is essential to emphasize that 
this was a sub-analysis of a prospective randomized control 
trial [13]. Since this was not a primary endpoint, it was not 
clear whether the unique biological characteristics of ful-
vestrant confer selective efficacy for non-visceral or visceral 
metastases. However, our findings agree with that of the pre-
viously reported data. The prognostic value of “PgR-positiv-
ity” has also been discussed previously. PgR-positivity was 
found to be associated with good outcomes in HR-positive 
breast cancers, indicating better baseline prognoses than in 
PgR-negative cases. The predictive value of PgR expression 
regarding the benefit from ET has also been evaluated [20, 
21]. Subgroup analysis from the same clinical trial showed 
that PgR-positivity resulted in superior PFS (hazard ratio: 
0·728, CI: 0·561–0·944) in patients treated with fulvestrant 
compared to that with AI alone [13]. Similar to our observa-
tions, these previous reports demonstrated good predictive 
value of PgR-positivity. Interestingly, “very low sensitivity” 
defined as recurrence within 2 years during adjuvant ET or 
progression within 3 months of initial ET, was also found 
to be a favorable predictive factor in our cohort. In the case 
of classical ET, the majority of this subset with “very low 
Fig. 2  Kaplan–Meier curves for overall survival. a All patients (N = 49), b fulvestrant (n = 40). CI confidence interval
Fig. 3  Kaplan–Meier curves for time to treatment failure. a All patients (N = 49), b fulvestrant (n = 40). CI confidence interval
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sensitivity” might receive first-line chemotherapy instead of 
second-line ETs after progression on the first-line ET [4]. 
The Hortobagyi algorism [4] was based on classical, and 
not next-generation ETs and targeted therapies [including, 
SERD, inhibitors of mTOR, poly ADP ribose polymerase 
(PARP), CDK, and immune checkpoints]. New agents with 
distinct mechanisms of action might help to establish next-
generation treatment strategies, and these analyses of predic-
tive markers need to be interpreted with caution. Previous 
reports suggest that ET with CDK inhibitors are effective 
for treating both visceral and non-visceral HR-positive and 
HER2-negative MBC in the first or second-line settings 
[22–24]. Distinct predictive markers need to be evaluated 
for various agents (i.e. SERMs, SERD, AIs, CDK inhibi-
tors, and PARP inhibitors) and settings (i.e. neoadjuvant, 
adjuvant, and first/second or later-line therapies). Our find-
ings also need to be validated in other independent datasets.
Our study has certain limitations. First, the sample size 
was small; therefore, our findings should be interpreted 
with caution. The heterogeneity of treatments (fulvestrant, 
SERMs, steroidal AI with an mTOR inhibitor, and AI) in our 
cohort might have affected the results. We performed only 
univariate analyses in this study and did not have enough 
sample size for multivariate analyses. Confounding factors 
might impact on our results. Moreover, the study did not aim 
to compare different treatment regimens. Assuming the use 
of an accurate binominal test with α = 0.05 (one-tailed) and 
β = 0.2, none of the subgroups (fulvestrant, SERMs, mTOR 
inhibitor, and AI) had 43 patients. Further, the recommended 
second-line ET regimen could not be identified as the fulves-
trant group with 40 cases as the largest subgroup. Second, 
being a cohort study, only registered patients were selected 
and cases might not have always been evenly distributed 
to each cohort. This hidden bias could misrepresent find-
ings to readers. Despite these limitations, our finding that 
second-line ETs provide clinical benefits for patients with 
poor sensitivities to initial ET was clinically significant, as 
the total number assessed in our cohort exceeded the mini-
mum number of estimated cases.
In conclusion, this study showed that second-line ET was 
effective and might be a valid option for the sequential treat-
ment of postmenopausal women with MBC with low and 
very low sensitivity to initial ET. Future studies based on 
larger and independent cohorts are needed to evaluate the 
predictive values of these treatment strategies and covari-
ates. Since prospective randomized control trials might not 
be feasible for this small population with low sensitivity to 
first-line ETs, cohort studies might be more suitable.
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